Keyphrases
Tumor
100%
Tumor Heterogeneity
50%
Immunoactivation
50%
Glioblastoma
50%
Oncolytic
50%
Clinical Trials
50%
Oncolytic Herpes Simplex Virus (oHSV)
37%
Recurrent Glioblastoma
25%
Nestin
25%
Serology
25%
Herpes Simplex Virus Type 1 (HSV-1)
25%
Tumor Microenvironment
18%
Peripheral Expansion
12%
Clonal Diversity
12%
Human Validation
12%
Intralesional
12%
Neurovirulence
12%
T-cell Count
12%
Single-cell RNA Sequencing (scRNA-seq)
12%
Specific T Cells
12%
Differentiated Tissues
12%
Adult Brain
12%
Biological Rationale
12%
Immunosuppressive Microenvironment
12%
Phase I Trial
12%
In Cancer
12%
Invasive Tumors
12%
First-in-human
12%
Improved Survival
12%
Dose-limiting Toxicity
12%
Virus
12%
Transcriptomic Signature
12%
Viral
12%
Immune Activation
12%
Anticancer Immune Response
12%
Cancer Therapeutics
6%
Specific Pattern
6%
Cell of Origin
6%
Cell-cell Interaction
6%
Cellular Processes
6%
Cell Atlas
6%
Nonmalignant
6%
Tumor Subtype
6%
Lineage-specific
6%
Cell State
6%
Malignant Cells
6%
Tumor Samples
6%
Non-malignant Cells
6%
Cancer Cells
6%
Program Analysis
6%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
50%
Herpesviridae
50%
Serology
50%
Human Alphaherpesvirus 1
50%
RNA Sequence
50%
T Cell
50%
Immune Response
25%
Transcriptomics
25%
Phase I Trials
25%
Promoter Region
25%
Carcinogenesis
25%
Cancer Cell
25%
Cell Cycle
25%
Cell Stress
25%
Anticancer
25%
Cell Count
25%
Immunity
25%
Medicine and Dentistry
Neoplasm
100%
Clinical Trial
50%
Glioblastoma
50%
Malignant Neoplasm
36%
Tumor Microenvironment
28%
Immunotherapy
20%
T Cell
20%
Human Alphaherpesvirus 1
20%
Nestin
20%
RNA Sequence
16%
Phase I Trials
10%
Promoter Region
10%
Transcriptomics
10%
Immunosuppressive Drug
10%
Immune Response
10%
Cell Count
10%
Immunity
10%
Cancer Cell
8%
Carcinogenesis
8%
Carcinoma Cell
8%
Epithelial Cell
8%
Cell Stress
8%
Cell Cycle
8%
